Abstract:ABSTRACT Objective To evaluate the impact of the first round of the National Centralized Drug Procurement (NCDP) pilot (referred to as “4+7” policy) on the use of policy-related original and generic drugs. Methods Drug purchase data from the China Drug Supply Information Platform (CDSIP) database were used, involving nine “4+7” pilot cities and 12 non-pilot provinces in China. “4+7” policy-related drugs were included, which consisted of 25 “4+7” List drugs and 97 alternative drugs that have an alternative relationship with “4+7” List drugs in clinical use. “4+7” List drugs were divided into bid-winning and non-winning products according to the bidding results. Purchase volume, purchase expenditures, daily costs were selected as outcome variables, and were measured using Defined Daily Doses (DDDs), Chinese Yuan (CNY), and Defined Daily Drug cost (DDDc), respectively. Difference-in-Difference (DID) method was employed to estimate the net effect of policy impact. Results After policy intervention, the DDDs of original drugs among “4+7” List drugs significantly reduced by 124.59%, while generic drugs increased by 52.12% (all p -values <0.01). 17.08% of the original drugs in DDDs were substituted by generic drugs. Prominent reductions of 121.69% and 80.54% were observed in the expenditure of original and generic drugs, with a total cost-saving of 5036.78 million CNY for “4+7” List drugs. The DDDc of bid-winning original and generic drugs, as well as non-winning original drugs, significantly decreased by 33.20%, 75.74%, and 5.35% (all p -values <0.01), while the DDDc of non-winning generic drugs significantly increased by 73.66% ( p <0.001). The use proportion of bid-winning products and non-winning original drugs raised prominently from 39.66% to 91.93% Conclusions “4+7” policy promoted the substitution use of generic drugs against original drugs, which conducive to drug costs saving. The overall quality level of drug use of public medical institutions significantly increased after “4+7” policy, especially in primary medical institutions. Strengths and limitations of this study ➢ The “4+7” policy is the first policy attempt of volume-based drug procurement work at the national level in China, and is a pioneering work in the reform of Drug Supply and Guarantee System in China. This study aimed to explored the effect of this policy on original and generic drug use in China. ➢ This study used data of national database – China Drug Supply Information Platform (CDSIP). The monthly drug purchase data of nine pilot cities and twelve non-pilot provinces in mainland China were analyzed. ➢ This study used Difference-in-Difference analysis to evaluate the policy effect. ➢ The findings based on drug purchase data rather than drug use data in the present study might limit the interpretation and extrapolation of research results.

Drug Price Index of Beijing and the Statistical Analysis

Study of the Antibacterials Purchase Price Trends from 1996 to 2005 of Beijing Sample Hospitals

Impact on Hospital Medicine After Adjusting the Drug Pricing Method

Trend Analysis of Drug Expenditure in China

International Comparison of Drug Price Level in China

Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis

Calculation and Analysis of Drug Expenditure in Shanghai from 2002 to 2009

Cause Analysis of High Price Differences Drugs Before and After the Deregulation of Drug Price Control: Empirical Study with big data on drug price data of 16 provinces in China

Changing Characteristics of Pharmaceutical Prices in China Under Centralized Procurement Policy: A Multi-Intervention Interrupted Time Series

Analysis of the "regulation of Drug Price Difference (trial Implementation)" in China

Impact of China’s National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: an Interrupted Time Series Analysis in Tianjin

Effects of Canceling Drug Price Addition Policy on the Change of Drug Structure in the Public Hospitals in Beijing City

The impact of separating drug sales from medical services reform on mechanism of controlling outpatient and emergency expenses in Beijing

The Effect of the Implementation of Low Price Medicine Policy on Medicine Price in China: A Retrospective Study

Trends in antidiabetic drug use and expenditure in public hospitals in Northwest China, 2012-21: a case study of Gansu Province

The influence of the national drug price negotiation policy reform on the medical expenses of patients in Xuzhou City: an interrupted time series analysis

Drug using survey in 12 hospitals in 7 provinces

Impact of Volume-Based Drug Procurement Policy on Drug Use Structure of Chinese Public Medical Institutions: A Difference-in-Difference Analysis of Nine Pilot Cities and Twelve Non-pilot Provinces

The impact of National Centralized Drug Procurement policy on the use of policy-related original and generic drugs in public medical institutions in China: A difference-in-difference analysis based on national database

The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China

Intended and Unintended Impacts of Price Changes for Drugs and Medical Services: Evidence from China.